Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis

[21] Schreiber BE(2015)Connective tissue disease-associated interstitial lung diseases (CTD-ILD) – report from OMERACT CTD-ILD Working Group J Rheumatol 42 2168-248

[22] Ong VH(2019)Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts Ann Rheum Dis 78 122-1925

[23] Rosenberg D(2019)Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease Eur Respir J 53 1802182-719

[24] Moinzadeh P(2018)Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease Respirology 23 385-2666

[25] Coghlan JG(2018)Assessing mortality models in systemic sclerosis-related interstitial lung disease Lung 196 409-2640

[26] Jaeger VK(2021)Treatment for systemic sclerosis-associated interstitial lung disease Curr Opin Rheumatol 33 240-974

[27] Wirz EG(2021)Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study Rheumatology (Oxford) 60 1915-218

[28] Allanore Y(2016)Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLSII): a randomised controlled, double-blind, parallel group trial Lancet Respir Med 4 708-1484

[29] Rossbach P(2006)Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 2655-106

[30] Riemekasten G(2018)Cyclophosphamide for connective tissue disease-associated interstitial lung disease Cochrane Database Syst Rev 1 CD010908-1339

[21] Schreiber BE(2015)Connective tissue disease-associated interstitial lung diseases (CTD-ILD) – report from OMERACT CTD-ILD Working Group J Rheumatol 42 2168-248

[22] Ong VH(2019)Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts Ann Rheum Dis 78 122-1925

[23] Rosenberg D(2019)Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease Eur Respir J 53 1802182-719

[24] Moinzadeh P(2018)Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease Respirology 23 385-2666

[25] Coghlan JG(2018)Assessing mortality models in systemic sclerosis-related interstitial lung disease Lung 196 409-2640

[26] Jaeger VK(2021)Treatment for systemic sclerosis-associated interstitial lung disease Curr Opin Rheumatol 33 240-974

[27] Wirz EG(2021)Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study Rheumatology (Oxford) 60 1915-218

[28] Allanore Y(2016)Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLSII): a randomised controlled, double-blind, parallel group trial Lancet Respir Med 4 708-1484

[29] Rossbach P(2006)Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 2655-106

[30] Riemekasten G(2018)Cyclophosphamide for connective tissue disease-associated interstitial lung disease Cochrane Database Syst Rev 1 CD010908-1339